Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
12 October 2023 - 12:15AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced two upcoming presentations at the 32nd European
Academy of Dermatology and Venerology (EADV) Congress in Berlin,
Germany, Oct. 11-14, 2023. The oral presentation will focus on
ANB032’s previously reported healthy volunteer Phase 1 data and the
trial-in-progress poster presentation will focus on ANB032’s Phase
2b study in moderate to severe atopic dermatitis.
The company’s planned activities are listed below and the full
preliminary program is available online on the EADV website.
Oral Presentation
ANB032, a novel BTLA agonist monoclonal antibody, inhibits T
cell proliferation, reduces inflammatory cytokines, and down
modulates BTLA expression on circulating T and B cells: Results
from a first-in-human Phase 1 study (abstract #5603)
- Session Title – FC05: Free communications in
biologics, immunotherapy and targeted therapy
- Session Date and Time – Friday, Oct. 13, 2023
from 8:30am – 10:40am CEST
- Presentation Time – 8:30am to 8:40am CEST
E-Poster Presentation
A Phase 2b, Randomized, Double-blind, Placebo-controlled,
Multi-center, Global Study to Evaluate the Efficacy and Safety of
ANB032 in the Treatment of Subjects with Moderate to Severe Atopic
Dermatitis (e-poster #P0558)
- Session Title – Atopic dermatitis/Eczema
- Session Date – Wednesday, Oct. 11,
2023
- Location – e-Poster Hall
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. It is developing
immune cell modulators, including two checkpoint agonists in
clinical-stage development, for autoimmune and inflammatory
disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the
treatment of moderate-to-severe rheumatoid arthritis; and ANB032,
its BTLA agonist, in a Phase 2b trial for the treatment of
moderate-to-severe atopic dermatitis. Its preclinical immune cell
modulator portfolio includes ANB033, an anti-CD122 antagonist
antibody for the treatment of autoimmune and inflammatory diseases.
In addition, Anaptys has developed two cytokine antagonists
available for out-licensing: imsidolimab, an anti-IL-36R
antagonist, in Phase 3 for the treatment of generalized pustular
psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the
treatment of respiratory disorders that is Phase 2/3 ready. Anaptys
has also discovered multiple therapeutic antibodies licensed to GSK
in a financial collaboration for immune-oncology, including an
anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)), an
anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an
anti-LAG-3 antagonist antibody (GSK4074386).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to: the company’s ability to find a licensing partner for
imsidolimab or etokimab and the timing of any such transaction.
Statements including words such as “plan,” “continue,” “expect,” or
“ongoing” and statements in the future tense are forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause its results to differ
materially from those expressed or implied by such forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that may cause the company’s actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company’s ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, the company’s ability to fund development
activities and achieve development goals, the company’s ability to
protect intellectual property and other risks and uncertainties
described under the heading “Risk Factors” in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Contact:Nick MontemaranoSenior Director,
Investor Relations and Strategic Communications
858.732.0178investors@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2024 to May 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From May 2023 to May 2024